PDCD1 and neoplasm: Inhibiting the androgen-AR axis reprograms the tumor microenvironment, enhancing effector T cell differentiation and improving the response to anti-PD-1 immunotherapy, highlighting the potential for targeting androgen signaling in cancer treatment (13).